Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell E, Raje N, Cook D, Yee AJ, Logan E, Avigan D, Jakubowiak AJ, Shaw KL, Daley H, Nikiforow S, Griffin FM, Cornwell C, Shen A, Heery C, Maus MV. Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2022 Apr 25.